GlassScriptPhysician profile
Katina L Thomas
NPI 1407995327
$2,414.80
in general payments reported to CMS, 2019-2025
12 companies · $962 in 2025
The $962 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $377 · 2023: $116 · 2024: $621 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.78 |
| Education | $290.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $701.62 | 2022-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $374.50 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $270.80 | 2021-2022 | |
| Axsome Therapeutics, INC. | $257.65 | 2024-2025 | Auvelity |
| Abbvie INC. | $153.28 | 2022 | |
| Acadia Pharmaceuticals INC | $147.43 | 2025 | Nuplazid |
| Tempus Ai, INC | $124.37 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $110.71 | 2025 | Cobenfy |
| Novo Nordisk INC | $98.45 | 2021 | |
| Neurocrine Biosciences, INC. | $88.53 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $70.88 | 2022-2025 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $16.58 | 2024 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katina Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.